ANLON HEALTHCARE LIMITED AHCL NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.anlon.in

Anlon Healthcare Limited manufactures and sells advance pharmaceutical intermediates in India and internationally. The company offers active pharmaceutical ingredients (API); nutraceutical API products; personal care ingredients; and veterinary API products. Its products are used in anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, antihypertensive, nutrition, anti-arrhythmic, anti-hyper parathyroid, antiplatelet, ant diabetic, gastroesophageal reflux disease (GERD), and anti-rheumatic therapeutics areas. The company was incorporated in 2013 and is based in Rajkot, India.

Market & Price

Market Cap

₹736.15 Cr

Current Price

₹13.85

High / Low (52W)

₹16.86 / ₹9.10

Beta

Valuation

Stock P/E

21.31

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹51.10

Price to Book

0.27

P/S

4.27

EV/EBITDA

2.64

Dividend Yield

Profitability & Returns

ROCE

25.29%

ROE

17.36%

ROA

10.41%

Profit Margin

16.56%

Op Margin

29.49%

EPS (Latest Qtr)

₹0.11

EPS (TTM)

₹0.65

Balance Sheet & Liquidity

Debt/Equity

0.17

Quick Ratio

1.00

Current Ratio

2.87

Debt

₹43.65 Cr

Total Assets

₹181.30 Cr

Current Assets

₹158.48 Cr

Working Capital

₹98.43 Cr

Ownership

Promoter Holding

84.67%

Chg in Prom Hold

FII / Inst Holding

0.00%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹126.24 Cr

Total Revenue (TTM)

₹172.22 Cr

EBITDA

₹47.77 Cr

Free Cash Flow

₹-118.02 Cr

Operating Cash Flow

₹-79.44 Cr

Shares Outstanding

₹53.15 Cr

Gross Margin

38.97%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

28.16%

Profit 5Y

6,383.66%

Revenue (YoY)

3.90%

Earnings (YoY)

-54.80%

PROS

Healthy ROCE of 25.3%.
Compounding revenue at 28.2% over 5 years.
Profit CAGR of 6383.7% over 5 years.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AHCL ANLON HEALTHCARE LIMITED NSEPHARMA	13.85	21.31	₹736.15 Cr	-	25.29%	17.36%	28.16%	6,383.66%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Sep 2025	Dec 2025
Revenue	24.17 Cr	9.36 Cr	48.93 Cr	52.20 Cr	35.58 Cr
Cost of Revenue	13.59 Cr	5.65 Cr	29.02 Cr	32.96 Cr	20.07 Cr
Gross Profit	10.58 Cr	3.71 Cr	19.91 Cr	19.24 Cr	15.51 Cr
Operating Expenses	3.53 Cr	3.14 Cr	3.08 Cr	5.96 Cr	3.52 Cr
Operating Income	7.05 Cr	57.66 L	16.83 Cr	13.29 Cr	11.99 Cr
EBITDA	7.57 Cr	59.55 L	17.29 Cr	13.77 Cr	12.54 Cr
Interest Expense	93.05 L	88.66 L	96.88 L	86.61 L	1.58 Cr
Pretax Income	6.16 Cr	-29.11 L	15.49 Cr	12.45 Cr	10.61 Cr
Tax Provision	3.57 Cr	2.19 Cr	-1.16 Cr	3.13 Cr	5.46 Cr
Net Income	2.59 Cr	-2.49 Cr	16.65 Cr	9.32 Cr	5.15 Cr
Diluted EPS	0.05	-0.05	-	0.18	0.11

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	57.14 Cr	112.88 Cr	66.58 Cr	120.29 Cr
Cost of Revenue	44.21 Cr	88.40 Cr	36.45 Cr	75.98 Cr
Gross Profit	12.94 Cr	24.47 Cr	30.13 Cr	44.31 Cr
Operating Expenses	9.22 Cr	13.41 Cr	16.29 Cr	13.41 Cr
Operating Income	3.72 Cr	11.06 Cr	13.84 Cr	30.90 Cr
EBITDA	5.84 Cr	12.65 Cr	15.72 Cr	32.43 Cr
Interest Expense	4.11 Cr	3.79 Cr	4.08 Cr	3.77 Cr
Pretax Income	-10.77 L	6.99 Cr	9.75 Cr	26.89 Cr
Tax Provision	0	1.17 Cr	9.40 L	6.37 Cr
Net Income	-10.77 L	5.82 Cr	9.66 Cr	20.52 Cr
Diluted EPS	-0.00	0.11	0.18	0.39

Compounded Sales Growth

5 Years:	28.16%
1 Year:	3.90%

Compounded Profit Growth

5 Years:	6,383.66%
1 Year:	-54.80%

Stock Price Performance

1 Year:	+50.99%
6 Months:	-13.01%
3 Months:	+18.72%
1 Month:	+4.14%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	84.97 Cr	111.55 Cr	128.00 Cr	181.30 Cr
Current Assets	57.74 Cr	85.81 Cr	100.70 Cr	158.48 Cr
Cash & Equivalents	1.54 Cr	62.36 L	2.27 Cr	1.45 Cr
Inventory	26.69 Cr	26.97 Cr	41.71 Cr	50.26 Cr
Receivables	20.30 Cr	43.81 Cr	38.73 Cr	75.00 Cr
Total Liabilities	83.42 Cr	104.17 Cr	106.97 Cr	100.88 Cr
Current Liabilities	28.89 Cr	43.55 Cr	50.10 Cr	60.05 Cr
Long Term Debt	52.27 Cr	58.18 Cr	54.25 Cr	38.36 Cr
Total Debt	62.38 Cr	70.32 Cr	81.25 Cr	66.55 Cr
Total Equity	1.55 Cr	7.37 Cr	21.03 Cr	80.42 Cr
Shares Outstanding	53.15 Cr	53.15 Cr	53.15 Cr	53.15 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	-1.75 Cr	-2.85 Cr	-3.23 Cr	-22.55 Cr
Investing Cash Flow	-38.60 L	-33.49 L	-3.37 Cr	2.79 Cr
Financing Cash Flow	2.81 Cr	2.27 Cr	8.25 Cr	18.94 Cr
Capital Expenditure	-47.84 L	-37.22 L	-3.53 Cr	-52.93 L
Free Cash Flow	-2.23 Cr	-3.22 Cr	-6.76 Cr	-23.08 Cr
Net Change in Cash	66.73 L	-91.87 L	1.65 Cr	-82.48 L

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	22.6%	21.7%	45.3%	36.8%
Operating Margin %	6.5%	9.8%	20.8%	25.7%
Net Margin %	-0.2%	5.2%	14.5%	17.1%
ROE %	-6.9%	78.9%	45.9%	25.5%
ROCE %	6.6%	16.3%	17.8%	25.5%

Shareholding Pattern

Insiders

84.67%

Institutions

0.00%

Public Float

0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AHCL

No recent headlines available.

AHCL · Healthcare